IRIS
DEFERRARI, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 18.600
Totale 18.600
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 18.600
Totale 18.600
Salva come PNG Salva come JPEG
Città #
Genova 14.508
Rapallo 2.153
Genoa 1.450
Vado Ligure 438
Bordighera 51
Totale 18.600
Salva come PNG Salva come JPEG
Nome #
L'AMMONIOGENESI RENALE NELL'UOMO 262
Chronic kidney disease in hypertension under specialist care: the I-DEMAND study 148
Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. 148
Interorgan exchange of aminothiols in humans 142
Androgen-mediated apoptosis of kidney tubule cells: role of c-Jun amino terminal kinase 141
Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy 136
Oxidative stress mediates apoptotic changes induced by hyperglycemia in human tubular kidney cells 136
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. 135
Ambulatory arterial stiffness index and renal abnormalities in primary hypertension 134
Inter-organ leptin exchange in humans 131
Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. 130
Vitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessions 128
C-reactive protein and target organ damage in untreated patients with primary hypertension. 128
Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. 128
Subclinical functional and structural renal abnormalities predict new onset type 2 diabetes in patients with primary hypertension 127
ABNORMALITIES IN AMINO ACID METABOLISM IN CHRONIC RENAL FAILURE 127
Correlation between pentosidine and endothelin-1 in subjects undergoing chronic hemodialysis. 126
Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. 125
Kidney protein dynamics and ammoniagenesis in humans with chronic metabolic acidosis 122
Creatinine clearance and early signs of target organ damage in primary hypertension 122
Free and sulfoconjugated catecholamines in normotensive uremic patients: effects of hemodialysis. 121
Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients 119
Mild renal dysfunction and renal vascular resistance in primary hypertension 119
Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. 119
Predicting cardiovascular risk using creatinine clearance and an artificial neural network in primary hypertension 119
Mechanisms of renal ammonia production and protein turnover 119
PROTEIN TURNOVER IN THE HUMAN KIDNEY 118
Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. 117
Arterial hypertension and microalbuminuria in IDDM: the Italian Microalbuminuria Study 117
Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients 117
Midwall fractional shortening identifies extracardiac organ damage in essential hypertension 116
METABOLIC SYNDROME AND CARDIOVASCULAR RISK IN PRIMARY HYPERTENSION. 116
Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II 115
Coronary flow reserve is impaired in hypertensive patients with subclinical renal damage 115
Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension. 115
AMINO ACID METABOLISM AND THE LIVER IN RENAL FAILURE 114
Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension 114
5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. 114
Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS 114
Phenylalanine hydroxylation across the kidney in humans 113
Renal ammoniagenesis in an early stage of metabolic acidosis in man 113
Renal and cardiac abnormalities in primary hypertension 111
LEG METABOLISM OF AMINO ACIDS AND AMMONIA IN PATIENTS WITH CHRONIC RENAL FAILURE 111
Blood pressure variability and multiple organ damage in primary hypertension 110
Renal metabolism of C peptide in type I (insulin-dependent) diabetic patients 109
Effects of a protein meal on blood amino acid profile in patients with chronic renal failure. 109
Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells 108
Splanchnic exchange of amino acids after amino acid ingestion in patients with chronic renal insufficiency 108
Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension 107
RENAL METABOLISM OF C-PEPTIDE IN MAN 107
Amino acid imbalance in patients with chronic renal failure. 107
Microalbuminuria and subclinical cerebrovascular damage in essential hypertension 105
EFFECTS OF CHRONIC RENAL INSUFFICIENCY AND METABOLIC ACIDOSIS ON GLUTAMINE METABOLISM IN MAN 105
Mild renal dysfunction and cardiovascular risk in hypertensive patients. 105
Treatment of diabetic nephropathy in its early stages 105
Disposal of exogenous amino acids by muscle in patients with chronic renal failure 104
Vascular permeability, blood pressure, and organ damage in primary hypertension 104
Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. 103
Serum uric acid as a marker of target organ damage in primary hypertension 103
LEUCINE METABOLISM AND PROTEIN DYNAMICS IN THE HUMAN KIDNEY 103
Renal ammoniagenesis in humans with chronic potassium depletion 103
SPLANCHNIC AMINO ACID AND PROTEIN TURNOVER IN HUMANS: INSIGHT FROM ISOTOPE DILUTION AND CATHETERIZATION STUDIES 102
Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure 101
Amino acid metabolism, substrate availability and the control of protein dynamics in the human kidney 101
Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension 101
INDIVIDUAZIONE DEL RUOLO DELLA GLUTAMINASI FOSFATO-DIPENDENTE E DELLA GLUTAMINASI FOSFATO-INDIPENDENTE NELLA PRODUZIONE RENALE DI AMMONIACA 100
Skeletal muscle protein synthesis and degradation in patients with chronic renal failure 100
Sub-clinical organ damage in hypertension and obesity 100
Abnormal amino acid metabolism after amino acid ingestion in chronic renal failure 99
Target organ damage and metabolic syndrome in non diabetic hypertensive patients 99
Global risk stratification in primary hypertension: the role of the kidney 99
RENAL AMMONIAGENESIS IN THE POST-PRANDIAL PERIOD 99
TT virus infection in haemodialysis patients 99
Renal ammoniagenesis during the adaptation to metabolic acidosis in man. 98
Renal metabolism of amino acids in early insulin-dependent diabetes mellitus 98
Muscle protein synthesis and degradation in hemodialysis (HD) patients with protein-energy malnutrition (PEM) 97
Abnormalities in amino acid metabolism in patients with chronic renal failure. A pathophysiological approach to the nutritional treatment. I. Studies in the postabsorptive state 97
Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised? 97
Mild hyperuricemia and subclinical renal damage in untreated primary hypertension 97
MICROALBUMINURIA, CARDIOVASCULAR, AND RENAL RISK IN PRIMARY HYPERTENSION. 96
Apoptosis induced by serum withdrawal in human mesangial cells. Role of IGFBP-3 96
BRAIN METABOLISM OF AMINO ACIDS AND AMMONIA IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY 96
Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC Study 95
Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria. 95
Serum uric acid levels predict new onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. 95
Left-ventricular hypertrophy and renal outcome in hypertensive patients in primary-care. 95
DETERMINANTS OF THE PARTITION OF RENAL AMMONIA PRODUCTION BETWEEN URINE AND VENOUS BLOOD IN MAN WITH METABOLIC ACID-BASE DISTURBANCES 95
WHOLE BODY AND ORGAN PROTEIN TURNOVER IN CHRONIC RENAL FAILURE 94
SUCCESSFUL TREATMENT OF MITOMYCIN C-ASSOCIATED HEMOLYTIC UREMIC SYNDROME BY PLASMAPHERESIS 94
Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. 94
Cardiovascular and renal risk assessment as a guide for treatment in primary hypertension. 93
Metabolic syndrome and microalbuminuria predict renal outcome in non-diabetic patients with primary hypertension: the MAGIC study. 93
Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. 92
Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension 92
Importance of blood pressure control in chronic kidney disease 92
EFFECTS OF HEMODIALYSIS ON GUANIDINO-PROPIONIC ACID METABOLISM 92
Role of blood cells in leucine kinetics across the human kidney 92
Left ventricular geometry and function in patients with essential hypertension and microalbuminuria 91
Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes. 91
Microalbuminuria blood pressure load, and systemic vascular permeability in primary hypertension 91
Totale 11.095
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.954
article - articoli 45.093
book - libri 0
conference - conferenze 2.726
curatela - curatele 0
other - altro 433
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.702
Totale 101.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.487 0 0 0 261 458 595 776 290 412 937 575 183
2020/20211.284 72 124 110 87 69 122 110 119 142 111 110 108
2021/20222.592 56 213 142 322 126 187 192 589 69 215 152 329
2022/20232.571 240 115 30 265 421 489 3 238 462 14 248 46
2023/20241.058 66 165 19 108 80 151 43 88 75 9 100 154
2024/2025462 45 254 86 77 0 0 0 0 0 0 0 0
Totale 18.732